Activated leukocyte cell adhesion molecule as a noninvasive biomarker in women with breast cancer

Abstract

Activated leukocyte cell adhesion molecule ALCAM/CD166 as a noninvasive diagnostic biomarker has the potential to revolutionize breast cancer screening by enabling early intervention and, ultimately improving patient survival rates This study investigates the ALCAM concentration and its diagnostic accuracy at the early stages of breast cancer T1 by T2 M0 N0 A total of 81 early breast cancer patients confirmed on histopathology and 81 healthy female volunteers whose breast ultrasound or mammogram were normal were included in the study Blood saliva and urine samples were collected from all the included participants centrifuged at 3000 RPM for 10 minutes and the supernatant was stored at 80 degree C until analyzed for ALCAM expression by using the Human ALCAM ELISA Kit Receiver Operating Curves ROC were used to evaluate the diagnostic performance of the ALCAM biomarker in serum saliva and urine and were 0 point 947 0 point 996 and 0 point 947 respectively The sensitivity specificity and cut off values of ALCAM expression in serum 87 point 7 84 and not greater than 49 point 5 saliva 95 point 5 96 point 3 and not greater than 52 point 5 and urine 88 point 89 point 89 point 19 and not greater than 55 were interpreted ALCAM can be used to detect early breast cancers showing better noninvasive diagnostic values With our study results we infer that ALCAM may represent a biomarker for breast cancer which may have potential utility as a diagnostic tool as per the sensitivity and specificity values obtained newline newline newline